GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (BUE:LLY) » Definitions » Cyclically Adjusted Price-to-FCF

Eli Lilly and Co (BUE:LLY) Cyclically Adjusted Price-to-FCF : 33.03 (As of Apr. 27, 2024)


View and export this data going back to . Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted Price-to-FCF?

As of today (2024-04-27), Eli Lilly and Co's current share price is ARS14229.00. Eli Lilly and Co's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was ARS430.73. Eli Lilly and Co's Cyclically Adjusted Price-to-FCF for today is 33.03.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

BUE:LLY' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 13.08   Med: 28.05   Max: 221.53
Current: 206.95

During the past years, Eli Lilly and Co's highest Cyclically Adjusted Price-to-FCF was 221.53. The lowest was 13.08. And the median was 28.05.

BUE:LLY's Cyclically Adjusted Price-to-FCF is ranked worse than
92.31% of 325 companies
in the Drug Manufacturers industry
Industry Median: 32.81 vs BUE:LLY: 206.95

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Eli Lilly and Co's adjusted free cash flow per share data for the three months ended in Dec. 2023 was ARS-3,136.157. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is ARS430.73 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted Price-to-FCF Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.22 44.71 68.58 84.88 164.46

Eli Lilly and Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.88 77.20 109.24 137.06 164.46

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted Price-to-FCF falls into.



Eli Lilly and Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Eli Lilly and Co's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=14229.00/430.73
=33.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Eli Lilly and Co's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-3136.157/129.4194*129.4194
=-3,136.157

Current CPI (Dec. 2023) = 129.4194.

Eli Lilly and Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 2.073 99.695 2.691
201406 24.124 100.560 31.047
201409 42.296 100.428 54.506
201412 21.538 99.070 28.136
201503 -15.652 99.621 -20.334
201506 20.080 100.684 25.811
201509 27.582 100.392 35.557
201512 21.484 99.792 27.862
201603 -20.518 100.470 -26.430
201606 61.004 101.688 77.640
201609 80.670 101.861 102.495
201612 91.879 101.863 116.735
201703 -38.584 102.862 -48.546
201706 89.186 103.349 111.684
201709 95.145 104.136 118.246
201712 91.478 104.011 113.825
201803 15.355 105.290 18.874
201806 -32.992 106.317 -40.161
201809 261.318 106.507 317.535
201812 121.835 105.998 148.756
201903 -14.190 107.251 -17.123
201906 148.099 108.070 177.357
201909 284.714 108.329 340.143
201912 427.559 108.420 510.371
202003 30.255 108.902 35.955
202006 592.894 108.767 705.469
202009 453.390 109.815 534.331
202012 354.493 109.897 417.467
202103 475.990 111.754 551.230
202106 517.852 114.631 584.657
202109 504.875 115.734 564.574
202112 768.995 117.630 846.071
202203 778.045 121.301 830.118
202206 197.081 125.017 204.021
202209 962.165 125.227 994.381
202212 758.873 125.222 784.311
202303 723.541 127.348 735.311
202306 -217.375 128.729 -218.541
202309 -2,818.424 129.860 -2,808.872
202312 -3,136.157 129.419 -3,136.157

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (BUE:LLY) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Eli Lilly and Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (BUE:LLY) Business Description

Industry
Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.